at Irvine, California and other locations
study started
estimated completion



The purpose of this registry is to assess clinical outcomes, and different factors that may affect these clinical outcomes such as systems of care, associated with the use of Covidien market-released neurothrombectomy devices intended to restore blood flow in patients experiencing acute ischemic stroke due to large intracranial vessel occlusion.


This is a prospective, multi-center, non-randomized, observational registry of acute ischemic stroke patients that have or will undergo treatment with the use of a Covidien market-released neurothrombectomy device (as the initial device used to remove the thrombus) within 8 hours of stroke symptom onset, at the discretion of the investigator and independent of participation in this registry. This registry may enroll up to 1000 patients.


Ischemic StrokeStrokeIschemiaCerebral Infarction


You can join if…

  • Patient or patient's legally authorized representative has given Informed Consent according to Good Clinical Practices (GCP) and/or IRB and/or local or institutional policies.
  • Patient has experienced an acute ischemic stroke due to large intracranial vessel occlusion (with associated symptoms) and has been or will be treated with a Covidien market-released neurothrombectomy device, as the initial device used to remove the thrombus.
  • Treatment within 8 hours of stroke onset.
  • Pre-Stroke Modified Rankin Scale (mRS) score ≤ 1 (immediately) prior to stroke onset.
  • Pre-treatment National Institutes of Health Stroke Scale (NIHSS) ≥ 8 and ≤ 30.

You CAN'T join if...

  • Concurrent participation in a multicenter randomized study.


  • University of California Irvine
    IrvineCalifornia92697United States
  • University of California Los Angeles
    Los AngelesCalifornia90095United States


in progress, not accepting new patients
Start Date
Completion Date
Medtronic Neurovascular Clinical Affairs
Study Type
Observational [Patient Registry]
Last Updated